Esperion Q4 2021 Earnings Report
Key Takeaways
Esperion reported a U.S. net product revenue of $12.2 million for Q4 2021, a 12% sequential increase. The company also achieved 90% MACE accumulation in the CLEAR Outcomes trial and secured $209 million in financing, extending its cash runway beyond the CLEAR Outcomes top-line results.
U.S. net product revenue grew 12% sequentially to $12.2 million.
Prescriptions grew 9% during the quarter, with approximately 70,000 patients having filled a prescription since launch.
Secured $209 million in financing, extending the cash runway beyond CLEAR Outcomes top-line results.
Achieved 90% MACE accumulation in the CLEAR Outcomes Trial in February 2022.
Esperion
Esperion
Esperion Revenue by Segment
Forward Guidance
Esperion provided financial outlook for the full year 2022, including estimates for Research and Development and Selling, General and Administrative expenses.
Revenue & Expenses
Visualization of income flow from segment revenue to net income